Topic
Biosimilars
856 published works
Big Molecule Watch
Alvotech’s BLA for Vedolizumab Biosimilar First to be Accepted by FDA
On June 8, Alvotech announced that the U.S. Food and Drug Administration (“FDA”) has accepted Alvotech’s Biologics License Application (“BLA”) for AVT16, a proposed interchangeable biosimilar to Takeda’s ENTYVIO (vedolizumab),…
Big Molecule Watch
Chime Biologics and Daewoong Pharmaceutical Partner on Dupilumab Biosimilar
On June 2, 2026, Chime Biologics and Daewoong Pharmaceutical announced a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Sanofi and Regeneron’s DUPIXENT. Chime…
Big Molecule Watch
Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars
By Alice Yoon
On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for BA6101 (denosumab; injection 60 mg) and…
Big Molecule Watch
Polpharma and Tuteur Enter License for the Commercialization of a Biosimilar Targeting Autoimmune Diseases in Latin America
By Riley Wyberg
On May 22, 2026, Polpharma Biologics announced that it had entered into an exclusive licensing agreement with Tuteur to commercialize a biosimilar targeting autoimmune diseases across Latin America, excluding Brazil. …
Big Molecule Watch
Samsung Bioepis Launches OPUVIZ in Europe
On May 29, 2026, Samsung Bioepis Co., Ltd. announced the European launch of OPUVIZ, a biosimilar referencing EYLEA (aflibercept). OPUVIZ will be available as a 40 mg/mL solution for injection.…
Big Molecule Watch
CHMP Adopts Positive Opinion for Ranibizumab Biosimilars VISLYFA and REXATILUX
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for two ranibizumab biosimilars, VISLYFA and REXATILUX, recommending granting of a marketing authorization. Ranibizumab is…
Big Molecule Watch
FDA Approves Shanghai Henlius Biotech IND for Cetuximab Biosimilar
On May 10, 2026, Shanghai Henlius Biotech announced that the FDA has approved its IND for a proposed biosimilar, HLX05-N, to Eli Lilly’s ERBITUX (cetuximab) product for the treatment of metastatic…
Big Molecule Watch
FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria; Janssen Seeks a Preliminary Injunction to Block Their Launch
By Sarah Adam
On May 15, 2026, the U.S. Food and Drug Administration (“FDA”) approved Accord BioPharma’s IMMGOLIS (golimumab-sldi) as an interchangeable biosimilar to Janssen’s SIMPONI® (golimumab), and IMMGOLIS INTRI (golimumab-sldi) as an…
Big Molecule Watch
International Biosimilars Updates
By Riley Wyberg
On April 21, 2026, Biocon announced that Health Canada granted a Notice of Compliance (NOC) for BOSAYATM (denosumab) and VEVZUOTM (denosumab), biosimilars of Amgen’s Prolia® (denosumab) and Xgeva® (denosumab). Denosumab…
Big Molecule Watch
Third Circuit Affirms Denial of Stelara Biosimilar Injunction
As previously reported, litigation between Johnson & Johnson and Janssen (“J&J”) and Samsung Bioepis (“Samsung”) involving Samsung’s Stelara biosimilar, PYZCHIVA (ustekinumab-ttwe) (previously known as SB17), was resolved via a settlement…